Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Rotterdam ProstateCancer Risk Calculator: Development and Usability Testing of the Mobile Phone App The use of prostatecancer screening tools that take into account relevant prebiopsy information (ie, risk calculators) is recommended as a way of determining the risk of cancer and the subsequent need for a prostate biopsy. This has the potential to limit prostatecancer overdiagnosis and subsequent overtreatment. mHealth apps are gaining traction in urological practice and are used by both (...) practitioners and patients for a variety of purposes.The impetus of the study was to design, develop, and assess a smartphone app for prostatecancer screening, based on the Rotterdam ProstateCancer Risk Calculator (RPCRC).The results of the Rotterdam arm of the European Randomized Study of Screening for ProstateCancer (ERSPC) study were used to elaborate several algorithms that allowed the risk of prostatecancer to be estimated. A step-by-step workflow was established to ensure that depending
Impact of Prostatic-specific Antigen Threshold and Screening Interval in ProstateCancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for ProstateCancer Centres. The European Randomised Study of Screening for ProstateCancer trial has shown a 21% reduction in prostatecancer (PC) mortality with prostate-specific antigen (PSA)-based screening. Sweden used a 2-yr screening interval and showed a larger mortality reduction than Finland with a 4-yr (...) between the Finnish and Swedish centres and estimated the impact of different screening protocols.If the Swedish screening protocol had been followed in Finland, 122 additional PC cases would have been diagnosed at screening, 84% of which would have been low-risk cancers, and four leading to PC death. In contrast, if a lower PSA threshold had been applied in Finland, at least 127 additional PC would have been found, with 19 PC deaths.The small number of deaths among cases that would have been
you like to save your information to view later? Create an account and sign in to keep your Decision box results and view them later. You can also: Continue without an account and print your profile when the process is completed ProstateCancer Screening Men between the ages of 55 and 69 with at least a 10-year life expectancy. Screening is appropriate for people who do not carry a disease that affects their life expectancy. The prostate-specific antigen (PSA) blood test is used to screen men (...) ProstateCancer Screening Boîte à décision | Box details Back to the Decision boxes × My account Creating an account and signing in will allow you to keep your Decision box results and view them later. I do not have an account Provide some personal information and create a user account allowing to save your Decision box results and view them later. You can also: I already have an account Please enter your email address and password to access your profile and consult your decision boxes. Email
Prostatecancer screening and early diagnosis Canadian Urological Association recommendations on prostatecancer screening and early diagnosis To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed. Besides, it's possible to , or you can view flippdf Either scripts and active content are not permitted to run or Adobe Flash Player version 10.0.0 or greater is not installed. Besides, it's possible to , or you can view flippdf
, Inc. Directory Publication. 2017 Authors' conclusions Rationale: Targeted magnetic resonance imaging (MRI)-guided biopsy techniques, such as MRI-guided in-bore (MRI-IB) biopsy, have been developed to increase identification of clinically significant prostatecancer without increasing the detection of clinically nonsignificant tumors. Technology Description: MRI-IB biopsy is a technique that uses MRI images captured in real time and processed by interventional planning software to help insert (...) provide accurate diagnostic and/or staging information for men with suspected or diagnosed prostatecancer? Does use of MRI-IB biopsy improve patient management or outcomes? Is MRI-IB biopsy safe? Have definitive patient selection criteria been established for MRI-IB-biopsy? Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Biopsy; Humans; Magnetic Resonance Imaging; Male; ProstaticNeoplasms Language Published English Country of organisation
Mindfulness-Based Cognitive Therapy in Advanced ProstateCancer: A Randomized Controlled Trial Purpose Advanced prostatecancer (PC) is associated with substantial psychosocial morbidity. We sought to determine whether mindfulness-based cognitive therapy (MBCT) reduces distress in men with advanced PC. Methods Men with advanced PC (proven metastatic and/or castration-resistant biochemical progression) were randomly assigned to an 8-week, group-based MBCT intervention delivered by telephone (n (...) = 94) or to minimally enhanced usual care (n = 95). Primary intervention outcomes were psychological distress, cancer-specific distress, and prostate-specific antigen anxiety. Mindfulness skills were assessed as potential mediators of effect. Participants were assessed at baseline and were followed up at 3, 6, and 9 months. Main statistical analyses were conducted on the basis of intention to treat. Results Fourteen MBCT groups were conducted in the intervention arm. Facilitator adherence ratings
prostate surgery. 2 2 Indications and current treatments Indications and current treatments 2.1 Prostatecancer is usually diagnosed after a blood test in primary care has shown elevated prostate-specific antigen (PSA) levels. A raised PSA is not diagnostic of prostatecancer and a prostate biopsy is required to confirm the diagnosis and further tests are required to stage the extent of the disease. A NICE guideline describes recommendations for the diagnosis and management of prostatecancer. 2.2 Most (...) prostatecancers are either localised or locally advanced at diagnosis. Localised prostatecancer does not usually cause any symptoms, but some men might have some urinary problems or erectile dysfunction. Current treatments for localised disease include active surveillance, radical prostatectomy, external beam radiotherapy and brachytherapy. Hormone therapy (androgen deprivation or anti-androgens) is usually the primary treatment for metastatic prostatecancer, but is increasingly being used
Detection of prostatecancer local recurrence following radical prostatectomy: assessment using a continuously acquired radial golden-angle compressed sensing acquisition To compare image quality and diagnostic performance for detecting local recurrence (LR) of prostatecancer after radical prostatectomy (RP) between standard dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) and a high spatiotemporal resolution, continuously acquired Golden-angle RAdial Sparse Parallel (...) acquisition employing compressed sensing reconstruction ("GRASP").A search was conducted for prostate MRI examinations performed in patients with PSA ≥0.2 ng/mL after RP in whom follow-up evaluation allowed classification as positive (≥50% PSA reduction after pelvic radiation or positive biopsy) or negative (<50% PSA reduction after pelvic radiation; spontaneous PSA normalization) for LR, yielding 13 patients with standard DCE (11 LR+) and 12 with GRASP (10 LR+). Standard DCE had voxel size 3.0 × 1.9
Prostatecancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis Bone lesions on prostate MRI often raise concern about metastases. This study aimed to evaluate the prevalence of bone metastases on staging prostate MRI and evaluate associations between their MRI features and clinical/pathologic characteristics.Retrospective, IRB-approved study of 3765 patients undergoing prostate MRI for newly diagnosed PCa between 2000 and 2014 (...) . The reference standard to calculate the prevalence of bone metastases was bone biopsy and/or ≥1-year follow-up after MRI. In a subsample of 228 patients, the MRI characteristics of bone lesions were recorded by two radiologists independently. Associations between MRI and clinical/pathologic findings, including National Comprehensive Cancer Network (NCCN) risk categories, were calculated.57/3765 patients (1.5%, 95% CI 1.2-2.0%) had bone metastases. No patient with NCCN low-risk PCa (Gleason < 7, PSA < 10 ng
Metastatic ProstateAdenocarcinoma to the Brain: Case Reports and Literature Review Cerebral metastasis secondary to prostaticadenocarcinoma is rare and it is usually a late complication in patients with widespread distant metastases. Here, we report two unusual cases of such a rare condition. Our first case presented with a large frontal contrast-enhancing lesion-associated calcification and a large tumor cyst as shown on computed tomography and magnetic resonance imaging. This is the fifth (...) reported case of prostatic metastasis manifesting as a cystic intraparenchymal tumor in the literature. The second case presented with a large soft tissue mass in the scalp and this lesion appeared to invade through the skull and into the middle cranial fossa. He was not known to have prostatecancer before his initial presentation and it was only diagnosed following histology results of the scalp lesion.
prostatectomy (RPX), radiation therapy (XRT) and watchful waiting/observation to provide the evidence base for treating men with clinically localised PCA. The Scandinavian ProstateCancer Group-4 (SPCG-4) trial randomised 695 men diagnosed in the pre-prostate-specific antigen (PSA) era, most had palpable disease, to surgery or observation. 1 After a median follow-up of 13.4 years, surgery reduced PCA deaths by 44% (HR=0.56; 95% CI 0.41 to 0.77; absolute risk reduction=11 percentage points). All-cause (...) mortality was reduced by 12.7 percentage points. Reductions were confined to men <65 years of age. The ProstateCancer Intervention Versus Observation Trial (PIVOT) randomised 731 men from the early PSA era to RPX or observation. 2 After a 10-year median follow-up, surgery did not reduce disease-specific mortality (HR=0.63; 95% CI 0.36 to 1.09). There was also no significant reduction for all-cause mortality. Absolute differences were <3 percentage points for PCA and all-cause mortality. However
of the guideline. This guideline updates a previous version: Rodrigues G, Yao X, Loblaw A, Brundage M, Chin J, Genitourinary CancerDisease Site Group. Low-dose rate brachytherapy for patients with low- or intermediate-risk prostatecancer. Toronto (ON): Cancer Care Ontario (CCO); 2012 Oct 31. 55 p. (Evidence-based series; no. 3-10). [165 references] This guideline meets NGC's 2013 (revised) inclusion criteria. UMLS Concepts ICD9CM (185), (60.5) MSH , , , , , , , , MTH , , , , , , , , PDQ , , , , SNOMEDCT_US (...) brachytherapy; no recommendation can be made for or against using 131 Cs or HDR monotherapy. Patients should be encouraged to participate in clinical trials to test novel or targeted approaches to this disease. None provided Prostatecancer Treatment Nuclear Medicine Oncology Radiation Oncology Surgery Urology Physicians To provide oncologists, other health care practitioners, patients, and caregivers with recommendations regarding the use of brachytherapy for patients with prostatecancer that includes
; Evidence Level: Grade B ) Effective shared decision making in prostatecancer care requires clinicians to inform patients about immediate and long-term morbidity or side effects of proposed treatment or care options. ( Clinical Principle ) Clinicians should inform patients about suitable clinical trials and encourage patients to consider participation in such trials based on eligibility and access. ( Expert Opinion ) Care Options by Cancer Severity/Risk Group Very Low-/Low-Risk Disease Clinicians (...) . ( Expert Opinion ) Intermediate-Risk Disease Clinicians should consider staging unfavorable intermediate-risk localized prostatecancer patients with cross sectional imaging (CT or magnetic resonance imaging [MRI]) and bone scan. ( Expert Opinion ) Clinicians should recommend radical prostatectomy or radiotherapy plus ADT as standard treatment options for patients with intermediate-risk localized prostatecancer. ( Strong Recommendation; Evidence Level: Grade A ) Clinicians should inform patients
stratified by cancer severity (or risk group) to facilitate care decisions and second, to guide the specifics of implementing the selected management options, including active surveillance, observation/watchful waiting, prostatectomy, radiotherapy, cryosurgery, high intensity focused ultrasound (HIFU) and focal therapy. Secondary or salvage treatment for localized prostatecancer that persists or recurs after primary definitive intervention, and primary treatment of locally advanced/metastatic disease (...) immediate and long-term morbidity or side effects of proposed treatment or care options. (Clinical Principle) 5. Clinicians should inform patients about suitable clinical trials and encourage patients to consider participation in such trials based on eligibility and access. (Expert Opinion) CARE OPTIONS BY CANCER SEVERITY/RISK GROUP Very Low-/Low-Risk Disease 6. Clinicians should not perform abdomino-pelvic CT or routine bone scans in the staging of asymptomatic very low- or low-risk localized prostate
to this disease. Additional information is available at and . INTRODUCTION Section: The goal of this update is to provide oncologists, other health care practitioners, patients, and caregivers with recommendations regarding the use of brachytherapy for patients with prostatecancer that includes the most recent evidence. Prostatecancer is the most commonly diagnosed cancer in men. In 2016, it is estimated that there will be 180,890 new cases, along with an estimated 26,120 deaths. For this reason (...) , there is great interest in finding optimum treatment strategies to reduce the burden of disease in this patient population. The Cancer Care Ontario systematic review and clinical practice guideline on low–dose rate (LDR) brachytherapy for patients with low- or intermediate-risk prostatecancer were both published in 2013, and since then randomized evidence has been made available that might alter the original recommendations. The goal of this joint update is to consider this new evidence and determine
Clinically Localized ProstateCancer: AUA/ASTRO/SUO Guideline ProstateCancer: Clinically Localized Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online (...) and second, to guide the specifics of implementing the selected management options, including active surveillance, observation/watchful waiting, prostatectomy, radiotherapy, cryosurgery, high intensity focused ultrasound (HIFU) and focal therapy. Secondary or salvage treatment for localized prostatecancer that persists or recurs after primary definitive intervention, and primary treatment of locally advanced/metastatic disease, are outside the scope of these guidelines. The content of these guidelines
in radical prostatectomy specimens. J Urol. 2005;174(3):903-907. 91. Zietman AL, Edelstein RA, Coen JJ, Babayan RK, Krane RJ. Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology. 1994;43(6):828-833. 92. Martino P, Scattoni V, Galosi AB, et al. Role of imaging and biopsy to assess local recurrence after definitive treatment for prostatecarcinoma (surgery, radiotherapy, cryotherapy, HIFU). World J Urol (...) Post-treatment Follow-up of ProstateCancer Revised 2017 ACR Appropriateness Criteria ® 1 Post-treatment Follow-up of ProstateCancer American College of Radiology ACR Appropriateness Criteria ® Post-treatment Follow-up of ProstateCancer Variant 1: Prostatecancer follow-up. Status post radical prostatectomy. Clinical concern for residual or recurrent disease. Procedure Appropriateness Category Relative Radiation Level C-11 choline PET/CT skull base to mid-thigh Usually Appropriate ??? MRI
-prostatecancerssuchascoloncan- cer,esophagealcancer,thyroidcancer,lungcancer,renal cell carcinoma, and brain tumours, as well as in benign tissue [1, 45–49].Sofar,avarietyofmainlycasereportsexistsshowing increased PSMA uptake in non-prostatecancer-related le- sions. An important pitfall is relevant PSMA ligand uptake in coeliac ganglia of the autonomic nervous system which is pronetobemisinterpretedasretroperitoneallymphnodeme- tastases . Moreover, uptake in Paget’s bone disease, in stellate (...) . Prostate-specific membrane antigen expression in normal and ma- lignanthumantissues.ClinCancerRes.1997;3:81–5. 2. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82:2256–61. 3. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostatecarcinoma with distant